Ind-Swift Laboratories Ltd received and forwarded a disclosure from Essix Biosciences Limited, made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The disclosure was received by the company on 12th October, 2026.

Nature of the Event

The disclosure pertains to the acquisition of equity shares by Essix Biosciences Limited (the Acquirer), which is part of the Promoter and Promoter Group of Ind-Swift Laboratories Ltd (the Target Company).

Details of Acquisition

Acquirer: Essix Biosciences Limited, acting on behalf of itself and 19 Persons Acting in Concert (PACs).

Himanshu Jain, Director of Essix Biosciences Limited, signed the disclosure.

Transaction: Acquisition of 14,00,000 (Fourteen Lakh) Equity Shares of face value ₹10 each.

Mode of Acquisition: The shares were acquired pursuant to the conversion of Fully Convertible Warrants.

Date of Allotment: October 08, 2026.

Mode of Allotment: Allotment of Fully Convertible Warrants through a Preferential Issue by the Target Company.

Shareholding Pattern Change

Before the Acquisition (Holding of Essix Biosciences Limited & PACs):

  • Shares carrying voting rights: 4,43,34,278 shares (42.93% of total voting capital / 47.18% of total diluted voting capital)
  • Essix Biosciences Limited: 3,28,82,521 shares (37.81% / 35.00%)
  • PACs: 44,51,757 shares (5.12% / 4.74%)
  • Warrants/Convertible Securities: 70,00,000 warrants (representing a potential 7.45% of diluted capital) held by Essix Biosciences Limited.

After the Acquisition (Holding of Essix Biosciences Limited & PACs):

The acquisition involved the conversion of 14,00,000 warrants into equity shares.

  • Shares carrying voting rights: 4,43,34,278 shares (43.84% of total voting capital / 47.18% of total diluted voting capital)
  • Essix Biosciences Limited: 3,42,82,521 shares (38.80% / 36.48%)
  • PACs: 44,51,757 shares (5.04% / 4.74%)
  • Warrants/Convertible Securities: 56,00,000 warrants (representing a potential 5.96% of diluted capital) remain with Essix Biosciences Limited.

Capital Structure Impact

The equity share capital of the company changed as a result of the allotment.

Pre-allotment Capital: ₹86,96,15,580, comprising 8,69,61,558 Equity Shares of ₹10 each.

Post-allotment Capital: ₹88,36,15,580, comprising 8,83,61,558 Equity Shares of ₹10 each.

Total Diluted Capital (Post-allotment): ₹93,96,15,580, comprising 9,39,61,558 Equity Shares of ₹10 each.